SOR-C27

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSOR-C27
Drug Alias NameSoricidin-derived C-series peptide therapeuticsSoricidin-derived N-series peptideSOR-N54SOR-C27
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersTransient receptor potential cation channel subfamily V member 6 antagonists
TargetsSodium channel alpha subunitTransient receptor potential cation channel subfamily V member 6
Therapy Area/IndicationsPainProstatic NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSoricimed
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSoricimed
Active IndicationsN/A
Inactive IndicationsPainProstatic NeoplasmsOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A